RS
NMRA icon

R Squared’s Neumora Therapeutics NMRA Stock Holding History

R Squared’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,381
Closed -$24.4K – 652
2025
Q3 		$24.4K Sell
13,381
-11,682
-47% -$18.9K 0.01% 523
2025
Q2 		$18.4K Buy
+25,063
New +$19K 0.01% 445
2025
Q1 		– Sell
-1,210
Closed -$12.8K – 1068
2024
Q4 		$12.8K Buy
+1,210
New +$14.5K 0.01% 1068

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

R Squared's NMRA Position: Q4 2025 in Review

R Squared sold out of Neumora Therapeutics (NMRA) in Q4 2025, closing a stake of 13,381 shares — an estimated $24.4K sold.

R Squared first reported a position in NMRA in Q4 2024 and held it in 3 quarters. The position peaked at $24.4K in Q3 2025. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

  • R Squared reported no remaining Neumora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • R Squared sold 13,381 Neumora Therapeutics shares in Q4 2025, an estimated $24.4K.
  • R Squared first reported a position in Neumora Therapeutics in Q4 2024 and held it in 3 quarters.
  • R Squared's Neumora Therapeutics position peaked at $24.4K in Q3 2025.
  • 102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.